Kevin Prier
Internal Medicine · Idaho Falls, IDNPI 1801393798
Payments from drug & device makers
Across 235 payments — averaging $12,177 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$2.8M
- Boehringer Ingelheim$7K
- Novo Nordisk AS$2K
- Boehringer Ingelheim International GmbH$672
- Lilly USA, LLC$440
- Corcept Therapeutics$211
- plus $2K from 30 others
Across 4 payments — averaging $260.54 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$1K
What the payments were for
- Travel & lodging$2,66547%
- Food & beverage$2,94652%
- Education$401%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 78 | $2,849,706 |
| Boehringer Ingelheim | 7 | $6,628 |
| Novo Nordisk AS | 2 | $2,000 |
| Boehringer Ingelheim International GmbH | 7 | $672 |
| Lilly USA, LLC | 27 | $440 |
| Corcept Therapeutics | 11 | $211 |
| Xeris Pharmaceuticals, Inc. | 11 | $201 |
| Insulet Corporation | 9 | $197 |
| Amgen | 12 | $195 |
| Medtronic | 7 | $168 |
| Dexcom, Inc. | 5 | $158 |
| Bayer | 9 | $145 |
| Inspire Medical Systems, Inc. | 2 | $101 |
| Novo Nordisk | 4 | $73 |
| Sanofi-aventis U.S. LLC | 3 | $71 |
| Boston Scientific | 4 | $65 |
| Novartis | 4 | $64 |
| Recordati_rare_diseases_inc. | 4 | $64 |
| Kyowa Kirin, Inc. | 3 | $55 |
| Tandem Diabetes Care, Inc. | 3 | $49 |
| Ascendis Pharma Endocrinology Inc | 3 | $47 |
| Averitas Pharma Inc. | 1 | $37 |
| Radius Health, Inc. | 2 | $36 |
| Eton Pharmaceuticals, Inc. | 2 | $34 |
| Amryt Pharma Holdings Ltd | 2 | $33 |
| Pfizer | 2 | $32 |
| Idorsia Pharmaceuticals US Inc | 2 | $27 |
| Aimmune Therapeutics, Inc. | 1 | $24 |
| Neurocrine Biosciences, Inc. | 1 | $24 |
| BETA Bionics, Inc. | 1 | $17 |
| Biomarin Pharmaceutical Inc. | 1 | $16 |
| Tolmar, Inc. | 1 | $16 |
| Madrigal Pharmaceuticals | 1 | $16 |
| Curonix LLC | 1 | $14 |
| Halozyme Inc | 1 | $14 |
| Rhythm Pharmaceuticals, Inc. | 1 | $14 |
How this compares
$2,861,663 in reported general payments places this provider in the 95th percentile of 289 internal medicine providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 585 | $643,174 |
| OzempicSemaglutide | 528 | $601,499 |
| JardianceEmpagliflozin | 202 | $202,133 |
| TrulicityDulaglutide | 124 | $151,886 |
| FarxigaDapagliflozin Propanediol | 108 | $89,947 |
| Tresiba Flextouch U-100Insulin Degludec | 107 | $71,029 |
| Tresiba Flextouch U-200Insulin Degludec | 41 | $61,877 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 57 | $54,584 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 30 | $42,094 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 354 | $41,189 |
| Humalog Kwikpen U-100Insulin Lispro | 115 | $32,454 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 66 | $31,137 |
| Novolog FlexpenInsulin Aspart | 133 | $31,026 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 43 | $30,467 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 33 | $29,329 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $440 | $812,847774 claims |
| Novo NordiskOzempic, Novolog | $73 | $606,900554 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $6,628 | $207,693214 claims |
| PfizerNurtec Odt, Eliquis | $32 | $39,06129 claims |
| Sanofi-aventis U.S. LLCLantus | $71 | $10,09152 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 289 internal medicine providers in Idaho.
Other internal medicine in Idaho Falls
- Susan WachterIdaho Falls$22K
- Ahmed MahmoodIdaho Falls$21K
- Brady CookIdaho Falls$6K
- Scott TaylorIdaho Falls$5K
- Johnathan LiljenquistIdaho Falls$525
- Leland KrantzIdaho Falls$447
- Alan AvondetIdaho Falls$411
- Margaret BakerIdaho Falls$403
- Marian ShawBoise$7.8M
- Hira SiktelChubbuck$4.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.